- Home
- OFRM vs FDMT Comparison
OFRM vs FDMT Comparison
Compare OFRM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFRM | FDMT |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.9M | 695.3M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OFRM | FDMT |
|---|---|---|
| Price | $15.85 | $11.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $24.94 | ★ $28.09 |
| AVG Volume (30 Days) | 375.1K | ★ 968.6K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $37.90 | N/A |
| Revenue Next Year | $32.78 | $55.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $14.00 | $6.96 |
| 52 Week High | $27.00 | $16.93 |
Technical Indicators
Market Signals| Indicator | OFRM | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 35.73 |
| Support Level | $15.72 | $8.43 |
| Resistance Level | $17.11 | $11.96 |
| Average True Range (ATR) | 0.75 | 0.85 |
| MACD | -0.08 | -0.18 |
| Stochastic Oscillator | 9.11 | 12.38 |
Price Performance
Historical ComparisonAbout OFRM Once Upon a Farm PBC
Once Upon a Farm PBC is a provider of baby food products. The company provides childhood nutrition with real, organic, farm-fresh food-made with no added sugar, no preservatives, and nothing artificial. Its products are available at retail customers, including Target, Whole Foods, Kroger, Walmart, Publix, and Wegmans. Its key products include Smoothies, Yogurt, Milk Shakes, Oat Bars, etc.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).